PRESS RELEASE

Launch of European Covid-19 trials coordination module website.

Paris, 28 June 2021

The coordination module of the EU-funded projects RECOVER\(^1\) and EU-RESPONSE\(^2\) has launched its website https://covid19trials.eu/en. It centralises information for academics and industry on access to the three large Pan-European adaptive platform trials currently underway: DisCoVeRy, EU-SolidAct & REMAP-CAP.

A coordinated Pan-European approach is essential for tackling the COVID-19 epidemic, and finding the most effective therapeutic solutions. EU-RESPONSE and RECOVER, share a joint coordination module that allows them to evaluate potential therapeutics for COVID-19, while avoiding duplications and maximizing the use of resources. The coordination module, composed of the Trial Coordination Board (TCB), the Joint Access Advisory Mechanism (JAAM) and the Adaptive Platform Trial Toolbox, ensures optimal coordination of trials in the EU and abroad and provides a single entry point for new study arms in the European COVID-19 adaptive platform trials. This module is coordinated by ECRIN and the Norwegian Institute of Public Health.

The dedicated website describes the different bodies that aid in the coordination of the COVID-19 clinical trials and the roles they have been conferred. It clearly outlines the specificities of the different trials and how researchers and industry can apply through the JAAM. The JAAM is the entryway for the European COVID-19 adaptive platform trials already implanted in over 16 European countries and beyond. It is the single body, common to the DisCoVeRy, EU-SolidAct and REMAP-CAP trials, that assesses requests from investigators or industry looking to test their compound in these trials. The website also contains resources that will help researchers looking to develop platform trials navigate the complexities of this novel trial methodology.

**Platform trials**

Platform trials, allow a multitude of different treatment options (arms) to be compared with a single control (arm). They enable ineffective arms to be stopped after an interim analysis and new treatment arms to be added and may run in a perpetual manner. To date, they have been used principally in the field of oncology and more recently for infectious diseases.

**About ECRIN**

ECRIN is the European Clinical Research Infrastructure Network, a public, non-profit organisation that provides expertise in clinical trial preparation, setup, and management, representing 12 European countries, over 350 million citizens, and dozens of multinational clinical trials. Together all members join forces in multinational clinical trials, a crucial role in the development of a Covid-19 vaccine and treatments.
Contact information

For more information visit the covid19trials website, or contact the coordination module covid19trials.eu@ecrin.org

1. EU-RESPONSE is supported by the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement number 101015736.

2. RECOVER is supported by the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement number 101003589.